Successfully completed Initial Public Offering (IPO) in February 2026, raising $172.5 million and listing on Nasdaq.Reported positive topline 12-month data from Phase 1/2 trial of the Bimatoprost Drug ...

ALC gains after launching Clareon TruPlus IOL, expanding its portfolio with enhanced depth of focus while maintaining high-quality distance vision.

Alcon (NYSE:ALC) announced today that it launched its Clareon TruPlus intraocular lens (IOL) technology in the U.S.

"Surgeons told us they were looking for an enhanced design monofocal that did not sacrifice distance vision quality. TruPlus ...

“This lens represents an important step forward for our patients,” said Dr. Steven J. Dell. “The TECNIS PureSee™ IOL offers something genuinely new: a premium extended depth of focus lens that doesn’t ...

The Vision business at Johnson & Johnson MedTech has hit its latest milestone, earning a significant regulatory nod for its ...

Cataract remains one of the biggest drivers of avoidable vision loss in India, and the scale of surgical demand is visible in ...

An expert MD reveals clear insights into cataract surgery, spotlighting the breakthroughs in treatment: "We live in a time of ...

Johnson & Johnson (NYSE: JNJ) announced U.S. Food and Drug Administration (FDA) approval of TECNIS PureSee IOL, an extended depth of focus (EDOF) intraocular lens (IOL) intended for use in cataract ...

Two non-bioerodible pads at the optic–haptic junction of a monofocal IOL release bimatoprost into aqueous humor for >3 years while remaining outside the visual axis. Randomization (2:1:1) compared 78 ...

97% of patients who received the BIM-IOL System off all topical IOP-lowering therapy at 12-months 100% of BIM-IOL System patients achieved 20/32 or better BCDVA and a mean BCDVA equivalent to 20/20 ...